The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson’s, finds a new study led by UCL researchers.
BRAF-MEK Inhibition Achieves ‘Near Universal’ Response in Rare Brain Tumor
Targeted BRAF-MEK inhibition resulted in a response in nearly all patients with untreated BRAF V600E–mutated papillary craniopharyngioma, according to results from a small phase II
July 13, 2023